Last updated: February 15, 2026
Product Overview
NDC 43975-0349 corresponds to Givlaari (givosiran), a prescription medication approved by the FDA in November 2019 for the treatment of acute hepatic porphyria (AHP). Givlaari is an RNA interference (RNAi) therapeutic targeting hepatic delta-aminolevulinic acid synthase 1 (ALAS1), reducing attacks associated with AHP.
Market Landscape
The AHP market is limited, with Givlaari being the first FDA-approved treatment. Its main competitor is Orphazyme's Arimoclomol (not approved in the U.S. for this indication) and off-label management approaches. A second drug, Silence's siRNA (e.g., lumasiran for other indications), has not entered the AHP market.
Market Dynamics
- Prevalence: AHP affects an estimated 5,000 to 10,000 patients globally, predominantly in Europe and the U.S.
- Unmet Need: Limited treatment options and high disease burden support niche market growth.
- Pricing: Givlaari's list price in the U.S. is approximately $675,000 annually per patient.
Pricing Analysis
| Parameter |
Details |
| Current list price (U.S.) |
$675,000 per year |
| Pricing rationale |
Reflects RNAi therapy complexity and rare disease status |
| Reimbursement coverage |
Primarily through private insurers, Medicare, Medicaid |
| Negotiated discounts |
Industry estimates suggest 10-20% average rebates, reducing net price to approximately $540,000–$607,500 annually |
Market Penetration and Revenue Projections
- Initial Adoption: Limited by small patient population, with a first-year market penetration of approximately 5-10%.
- Growth Drivers: Increased diagnosis rates, expanded awareness, and indication expansion (e.g., prophylactic use).
- Forecast (2023-2028):
- Year 1 (2023): $70M–$135M (based on 5-10% penetration of an estimated 1,000 eligible patients in the U.S.)
- Year 3 (2025): $200M–$300M, assuming market share increases to 20%, with incremental growth in patient diagnosis
- Year 5 (2027): $300M–$400M, driven by broader adoption and international expansion
Global Market Considerations
- Europe: Pricing centers around €400,000–€500,000, with reimbursement variations.
- Asia-Pacific: Limited currently, but price per dose generally lower.
- Regulatory expansion in Japan, Canada, and Australia could boost revenues.
Economic and Competitive Factors
- Givlaari's high cost raises concerns over payer reimbursement and patient access.
- Biosimilar or generic development is unlikely in the near term due to the novelty of RNAi technology and patent protections.
- The continued innovation in gene therapy may impact long-term market share.
Price Projection Summary
| Year |
Estimated Net Price (USD) |
Market Penetration |
Revenue Range (USD) |
| 2023 |
$540,000 |
5% |
$70M–$75M |
| 2024 |
$560,000 |
8% |
$114M–$136M |
| 2025 |
$580,000 |
15% |
$174M–$174M |
| 2026 |
$600,000 |
20% |
$240M–$300M |
| 2027 |
$610,000 |
25% |
$305M–$400M |
Key Takeaways
- Givlaari remains a high-cost, niche therapy with limited but growing market penetration.
- Its price is aligned with other RNAi and rare disease treatments but faces pressure from payers.
- International expansion and diagnosis awareness are critical to revenue growth.
- Competition from emerging gene therapies or alternative modalities could impact long-term pricing and market share.
FAQs
-
What factors influence Givlaari's pricing?
The gene therapy's complexity, rarity of AHP, high development costs, and regulatory exclusivity primarily determine its high list price.
-
How do payers manage the high cost of Givlaari?
Rebate agreements, prior authorization, and patient assistance programs are common strategies to control expenditures.
-
Could biosimilars or generics emerge for Givlaari?
Unlikely in the near term due to the novelty of RNAi platforms and patent protections.
-
What are the main drivers of revenue growth?
Increased diagnosis, expanded treatment indications, improved access, and international approvals.
-
What is the outlook for price reductions?
Significant reductions are unlikely without biosimilar development, but discounts via payor negotiations may persist.
References
[1] Food and Drug Administration. "Givlaari (givosiran) Approval.' November 2019.
[2] IQVIA. "Global Oncology Market Data," 2022.
[3] National Organization for Rare Disorders. "Acute Hepatic Porphyria," 2022.
[4] EvaluatePharma. "Specialty Drugs Market," 2022.
